• 花蓮慈濟醫院核子醫學科副主任
• 教育部部定副教授
• 中華民國核醫學會理事
• 慈濟大學醫學系副教授
• 慈濟大學醫學系核子醫學科主任

• Best abstract award from Taiwan, Annual Congress of the Societyof Nuclear Medicine and Molecular Imaging, 2016 (San Diego, USA)
• Poster award, Clinical Oncology, Annual Congress of the Societyof Nuclear Medicine and Molecular Imaging, 2016 (San Diego, USA)
• Presentation selected for Highlight Talking, Annual Congress of the Societyof Nuclear Medicine and Molecular Imaging, 2016 (San Diego, USA)

• 林口長庚醫院核子醫學科科主任
• 基隆長庚醫院核子醫學科科主任
• 嘉義長庚醫院核子醫學科科主任
• 林口長庚醫院核子醫學科主治醫師
• 核子醫學科專科醫師證書(Nuclear medicine)
• 中華民國核醫學學會(Society of Nuclear Medicine – Taiwan)
• 台灣醫學會(Formosan Medical Association)

個人網站:https://www.researchgate.net/profile/Sheng-Chieh-Chan

科技部研究案（Supported by Ministry of Science and Technology, Taiwan）

• NSC 107-2314-B-182A-064; NSC 108-2314-B-182A-021; NSC 109-2314-B-303-009
• NSC 110-2314-B-303-014

期刊論文(Journal publication)

1. Prognostic Utility of 18F-FDG PET/MRI with Intravoxel Incoherent Motion Imaging in Nasopharyngeal Carcinoma. Eur J Nucl Med Mol Imaging. 2025 Jul 2. doi: 10.1007/s00259-025-07425-6. (First author).

2. Investigation of the diagnostic and prognostic impact of posttreatment fluorine-18 fluorodeoxyglucose PET/computed tomography on M0 esophageal cancer. Nucl Med Commun. 2025 Sep 1;46(9):816-823. (Corresponding author).

3. 18F-FET PET/CT can aid in diagnosing patients with indeterminate MRI findings for brain tumors: a prospective study. Ann Nucl Med. 2024 Nov 26. doi: 10.1007/s12149-024-02005-4. (First author)

4. Genomic and Glycolytic Entropy Are Reliable Radiogenomic Heterogeneity Biomarkers for Non-Small Cell Lung Cancer. Int J Mol Sci. 2023 Feb 16;24(4):3988. doi: 10.3390/ijms24043988. (SCI A)

5. Baseline and interim [18F]FDG-PET/MRI to assess treatment response and survival in patients with M0 esophageal squamous cell carcinoma treated by curative-intent therapy. Cancer Imaging. 2023;23:109. (Corresponding author)

6. Prospective Investigation of 18FDG-PET/MRI with Intravoxel Incoherent Motion Diffusion-Weighted Imaging to Assess Survival in Patients with Oropharyngeal or Hypopharyngeal Carcinoma. Cancers (Basel). 2022; 14(24):6104. (first author)

7. Radiomics for Predicting Survival in Patients with Locally Advanced Hypopharyngeal Cancer Treated with Concurrent Chemoradiotherapy. Cancers (Basel). 2022; 14(24):6119. (SCI A)

8. Association of early changes of circulating cancer stem-like cells with survival among patients with metastatic breast cancer. Ther Adv Med Oncol. 2022 Jul 15;14:17588359221110182. doi: 10.1177/17588359221110182. eCollection 2022. (SCI A)

9. Tumor glycolytic heterogeneity improves detection of regional nodal metastasis in patients with lung adenocarcinoma. Ann Nucl Med. 2022 Mar;36(3):256-266. doi: 10.1007/s12149-021-01698-1. (SCI A)

10. 18F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs. Cancers (Basel). 2022, 14(6), 1507. (SCI A)

11. Prognostic Value of Combing Primary Tumor and Nodal Glycolytic-Volumetric Parameters of 18F-FDG PET in Patients with Non-Small Cell Lung Cancer and Regional Lymph Node Metastasis. Diagnostics (Basel). 2021 Jun 9;11(6):1065. doi: 10.3390/diagnostics11061065. (Corresponding author)

12. Prospective comparison of early interim 18F-FDG-PET with 18F-FLT-PET for predicting treatment response and survival in metastatic breast cancer. BMC Cancer. 2021;21(1):908. (Corresponding author)

13. Predicting the risk of interval distant metastases in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy. J Formos Med Assoc. 2021. doi:10.1016/j.jfma.2021.06.002. (SCI A)

14. Combing MRI Perfusion and 18F-FDG PET/CT Metabolic Biomarkers Helps Predict Survival in Advanced Nasopharyngeal Carcinoma: A Prospective Multimodal Imaging Study. 2021; 28;13:1550. doi: 10.3390/cancers13071550. (First author)

15. Prognostic Value of Baseline Radiomic Features of 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma. Diagnostics (Basel). 2020;11:36. doi:10.3390/diagnostics11010036. (SCI A)

16. Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma. PLoS One. 2020; 28;15:e0244502. doi: 10.1371/journal.pone.0244502. (Corresponding author)

17. Preoperative F-18 fluorocholine PET/CT for the detection of hyperfunctioning parathyroid glands in patients with secondary or tertiary hyperparathyroidism: comparison with Tc-99m sestamibi scan and neck ultrasound. Ann Nucl Med. 2020;34:527-537. doi: 10.1007/s12149-020-01479-2. (Corresponding author)

18. Multiparametric PET/MRI in nasopharyngeal carcinoma: correlations between MRI functional parameters and 18F-FDG PET imaging biomarkers and their predictive value for treatment failure. Tzu Chi Med J. 2020;33:61-69. doi: 10.4103/tcmj.tcmj_4_20. (First author)

19. Pretreatment 18F-FDG PET/CT texture parameters provide complementary information to Epstein-Barr virus DNA titers in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2020;104:104628. doi:10.1016/j.oraloncology.2020.104628. (SCI A)

20. Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated With Definitive Chemoradiotherapy. Cancers (Basel) . 2020;12:607. doi: 10.3390/cancers12030607. (SCI A)

21. Radiation safety assessment of caregivers of thyroid cancer patients treated with 131I in Taiwan. Radiation Physics and Chemistry. 2020;172:108781. DOI: 10.1016/j.radphyschem. 2020.108781.

22. Comparison of 18F-FDG PET/MRI, MRI, and 18F-FDG PET/CT for the detection of synchronous cancers and distant metastases in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2020;47:94-104. (Co-first author)

23. Baseline circulating stem-like cells predict survival in patients with metastatic breast cancer. BMC Cancer. 2019;19:1167. (SCI A)

24. Textural features on 18F-FDG PET/CT and dynamic contrast-enhanced MR imaging for predicting treatment response and survival of patients with hypopharyngeal carcinoma. Medicine (Baltimore). 2019;98:e16608. (Co-first author)

25. Combining the radiomic features and traditional parameters of 18F-FDG PET with clinical profiles to improve prognostic stratification in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery. Ann Nucl Med. 2019;33:657-670. (Corresponding author)

26. Value of early evaluation of treatment response using 18F-FDG PET/CT parameters and the Epstein-Barr virus DNA load for prediction of outcome in patients with primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2019;46:650-660. (Corresponding author)

27. Clinical utility of simultaneous whole-body 18F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2018;45:1297-1308. (First author)

28. Predictive value of 1H MR spectroscopy and 18F-FDG PET/CT for local control of advanced oropharyngeal and hypopharyngeal squamous cell carcinoma receiving chemoradiotherapy: a prospective study. Oncotarget. 2017;14;8:115513-115525.

29. Correlation between overall survival and differential plasma and tissue tumor marker expression in nasopharyngeal carcinoma patients with different sites of organ metastasis. Oncotarget. 2016;7:53217-53229.

30. Higher body weight and distant metastasis are associated with higher radiation exposure to the household environment from patients with thyroid cancer after radioactive iodine therapy. Medicine (Baltimore). 2017;96:e7942. (SCI A)

31. Multiparametric imaging using 18F-FDG PET/CT heterogeneity parameters and functional MRI techniques: prognostic significance in patients with primary advanced oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. Oncotarget. 2017;8:62606-62621. (First author)

32. Tumor heterogeneity measured on F-18 fluorodeoxyglucose positron emission tomography/computed tomography combined with plasma Epstein-Barr Virus load predicts prognosis in patients with primary nasopharyngeal carcinoma. Laryngoscope. 2017;127:E22-E28. (First author)

33. Efficacy of vancomycin-releasing biodegradable poly(lactide-co-glycolide) antibiotics beads for treatment of experimental bone infection due to Staphylococcus aureus. J Orthop Surg Res. 2016;11:52. (SCI A)

34. Dynamic contrast-enhanced MRI, diffusion-weighted MRI and 18F-FDG PET/CT for the prediction of survival in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation. Eur Radiol. 2016; 26:4162-4172. (SCI A)

35. Pretreatment Dynamic Contrast-Enhanced MRI Improves Prediction of Early Distant Metastases in Patients With Nasopharyngeal Carcinoma. Medicine (Baltimore). 2016;95:e2567. doi: 10.1097/MD.0000000000002567. (SCI A)

36. F-18 FDG PET/CT as a Surveillance Tool for the Detection of Locoregionally Advanced Nasopharyngeal Carcinoma Recurrences in an Endemic Area. Annals of Nuclear Medicine and Molecular Imaging. 2016;29:10-22. (First author)

37. Clinical utility of multimodality imaging with dynamic contrast-enhanced MRI, diffusion-weighted MRI, and 18F-FDG PET/CT for the prediction of neck control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation. PLoS One. 2014;9:e115933. (SCI A)

38. Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma. World J Surg Oncol. 2014;12:170. DOI: 10.1186/1477-7819-12-170. (SCI A)

39. Detection of synchronous cancers by fluorodeoxyglucose positron emission tomography/computed tomography during primary staging workup for esophageal squamous cell carcinoma in Taiwan. PLoS One. 2013;8:e82812. eCollection 2013. DOI: 10.1371/journal.pone.0082812. (SCI A)

40. Interval Between Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma: Does Delayed Surgery Impact Outcome? Ann Surg Oncol. 2013:20:4245–4251. DOI:10.1245/s10434-013-3139-7. (SCI A)

41. Dynamic contrast-enhanced MR imaging predicts local control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. PLoS One. 2013:7;8:e72230. DOI:10.1371/journal.pone.0072230. (SCI A)

42. Clinical scenario of EBV DNA follow-up in patients of treated localized nasopharyngeal carcinoma. Oral Oncol. 2013;49:620-625. DOI:10.1016/j.oraloncology.2013.02.006. (SCI A)

43. Prognostic implications of post-therapy 18F-FDG PET in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Ann Nucl Med. 2013;27:710-719. (First author)

44. Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. Head Neck. 2012;34:1064-1070. (SCI A)

45. Misinterpretation of FDG-avid Pelvic Lymph Node Lesions as Distant Failure in a Patient with Recurrent Lung Cancer. Annals of Nuclear Medicine and Molecular Imaging. 2012;25:206-210.

46. Pretreatment (18)F-FDG PET standardized uptake value of primary tumor and neck lymph nodes as a predictor of distant metastasis for patients with nasopharyngeal carcinoma. Oral Oncol. 2013;49:169-174. DOI:10.1016/j.oraloncology.2012.08.011. (SCI A)

47. The role of (18)F-FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2013;49:71-78. DOI:10.1016/j.oraloncology.2012.07.016. (First author, IF=6.8)

48. Utility of 18F-fluoride PET/CT and 18F-FDG PET/CT in the Detection of Bony Metastases in Heightened-risk Head and Neck Cancer Patients. J Nucl Med. 2012;53:1730-1735. DOI:10.2967/jnumed.112.104893. (First author, IF=10.057)

49. Uterine cervical melanoma presenting with rapid progression detected by PET/CT. Acta Radiologica. 2012;1:16. DOI:10.1258/arsr.2012.120026. (SCI A)

50. Prognostic Significance of 18F-FDG PET Parameters and Plasma Epstein-Barr Virus DNA Load in Patients with Nasopharyngeal Carcinoma. J Nucl Med. 2012;53:21-28. DOI: 10.2967/jnumed.111.090696. (SCI A)

51. Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification. Nucl Med Commun. 2011;32:989-996. DOI:10.1097/MNM.0b013e3283495662. (First author, SCI A)

52. Comparison of PET/CT and MRI for the detection of bone marrow invasion in patients with squamous cell carcinoma of the oral cavity. Oral Oncol. 2011; 47:288-295. DOI:10.1016/j.oraloncology.2011.02.010. (SCI A)

53. 18F-FDG PET/CT and 3.0 Tesla Whole-body MRI for the Detection of Distant Metastases and Second Primary Tumors in Patients with Untreated Oropharyngeal/Hypopharyngeal Carcinoma: A Comparative Study. Eur J Nucl Med Mol Imaging. 2011;38:1607-1619. DOI:10.1007/s00259-011-1824-y. (First author, , IF=9.236)

54. PET/CT and 3-T whole-body MRI in the detection of malignancy in treated oropharyngeal and hypopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2011;38:996-1008. DOI: 10.1007/s00259-011-1740-1. (SCI A)

55. Pretreatment evaluation of distant-site status in patients with nasopharyngeal carcinoma: accuracy of whole-body MRI at 3-Tesla and FDG-PET-CT. Eur Radiol. 2009;19:2965-2976. DOI: 10.1007/s00330-009-1504-5. (SCI A)

56. Comprehensive imaging of residual/ recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT. Eur Radiol. 2010; 20:2229-2240. DOI:10.1007/s00330-010-1784-9. (SCI A)

57. 18F-FDG PET for retropharyngeal lymph node metastasis in oropharyngeal and hypopharyngeal cancers: impact on diagnosis and prediction analysis. Nucl Med Commun. 2010;31:260-265. DOI:10.1097/MNM.0b013e3283360133. (First author, SCI A)

58. Pretreatment T3-4 Stage is an Adverse Prognostic Factor in Patients with Esophageal Squamous Cell Carcinoma Who Achieve Pathological Complete Response Following Preoperative Chemoradiotherapy. Ann Surg. 2009;249:392-396. DOI: 10.1097/SLA.0b013e3181949e9f. (SCI A)

59. Red blood cell scintigraphy in children with acute massive gastrointestinal bleeding. Pediatrics International. 2008;50:199-203. DOI:10.1111/j.1442-200X.2008.02552.x.

60. Salvage surgery after failed chemoradiotherapy in squamous cell carcinoma of the esophagus. Eur J Surg Oncol. 2009;35:289-294. DOI:10.1016/j.ejso.2008.02.014. (SCI A)

61. Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging. 2009;36:12-22. DOI:10.1007/s00259-008-0918-7. (SCI A)

62. Distant metastases and synchronous second primary tumors in patients with newly diagnosed oropharyngeal and hypopharyngeal carcinomas: evaluation of (18)F-FDG PET and extended-field multi-detector row CT. Neuroradiology. 2008;50:969-79 DOI:10.1007/s00234-008-0426-2. (SCI A)

63. Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: The role of standardized uptake value. Oral Oncol. 2009;45:52-8. DOI:10.1016/j.oraloncology.2008.03.010. (First author)

64. Intractable bleeding from solitary mandibular metastasis of hepatocellular carcinoma. World J Gastroenterol. 2007;13:4526-4528. (SCI A)

65. 18F-FDG PET can replace conventional work-up in primary M staging of nonkeratinizing nasopharyngeal carcinoma. J Nucl Med. 2007;48:1614-1619. DOI:10.2967/jnumed.107.043406. (SCI A)

66. Prospective Study of [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography and Magnetic Resonance Imaging in Oral Cavity Squamous Cell Carcinoma With Palpably Negative Neck. J Clin Oncol. 2006;24:4371-4376. DOI:10.1200/JCO.2006.05.7349. (SCI A)

67. Differential Roles of 18F-FDG PET in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma after Primary Curative Therapy: Response Evaluation and Impact on Management. J Nucl Med. 2006; 47:1447-1454. (First author, IF=10.057)

68. Advantages and pitfalls of 18F-fluoro-2-deoxy-D-glucose Positron Emission Tomography in detecting locally residual or recurrent nasopharyngeal carcinoma: comparison with Magnetic Resonance Imaging. Eur J Nucl Med Mol Imaging. 2006;33:1032-1040.DOI:10.1007/s00259-005-0054-6. (First author, IF=9.236)

69. (18)F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for Stage T4 nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 65:1307-1314. DOI: 10.1016/j.ijrobp.2006.02.031. (SCI A)

70. Upper pole of a duplex kidney mimicking adrenal incidentaloma in 18F-fluoro-2-deoxy-D-glucose positron emission tomography: a pitfall in diagnosis. Br J Radiol. 2006; 79:50-52. (First author, SCI A)

71. [18F]fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. 2006; 24:599-604. DOI:10.1200/JCO.2005.03.8760. (SCI A)

72. Staging of untreated squamous cell carcinoma of buccal mucosa with 18F-FDG PET: comparison with head and neck CT/MRI and histopathology. J Nucl Med. 2005;46:775-781. (SCI A)

73. The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx. J Nucl Med. 2005;46:405-410. (SCI A)

74. Nasopharyngeal carcinoma staging by (18)F-fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2005;62:501-507. DOI: 10.1016/j.ijrobp.2004.09.057. (SCI A)

75. 18F-FDG PET and CT/MRI in Oral Cavity Squamous Cell Carcinoma: A Prospective Study of 124 Patients with Histologic Correlation. J Nucl Med. 2005;46:1136-1143. (SCI A)

76. Clinical Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Lung Cancer: Experience of Linko Chang-Gung Memorial Hospital. Ann Nucl Med Sci. 2005;18:67-77. (First author)

77. Are dual-phase (18)F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes? Eur J Nucl Med Mol Imaging. 2005;32:541-548.DOI:10.1007/S00259-004-1719-2. (SCI A)

78. False-Positive Findings on F-18 Fluoro-2-deoxy-D-glucose Positron Emission Tomography in a Patient With Nasopharyngeal Carcinoma and Extensive Sinusitis. Clin Nucl Med. 2005;30:62–63. DOI:10.1200/JCO.2010.28.7052. (First author, SCI A)

79. Clinical usefulness of 18F-FDG PET in nasopharyngeal carcinoma patients with questionable MRI findings for recurrence. J Nucl Med. 2004;45:1669-1676. (SCI A)

80. Nodal metastases of nasopharyngeal carcinoma: patterns of disease on MRI and FDG PET. Eur J Nucl Med Mol Imaging. 2004;31:1073-1080. DOI:10.1007/S00259-004-9. (SCI A)

81. False positive fluorine-18 fluorodeoxy-D-glucose positron emission tomography finding caused by osteoradionecrosis in a nasopharyngeal carcinoma patient. Br J Radiol. 2004;77:257-260. DOI: http://dx.doi.org/10.1259/bjr/69516821. (SCI A)

82. Diffuse cutaneous plasmacytomas demonstrated on gallium-67 imaging. Kaohsiung J Med Sci. 2003;19:193-5.

83. Diagnosis of Bile Peritonitis Caused by Rupture of Choledochal Cyst via 99mTc-DISIDA Cholescintigraphy: A Case Report. Ann Nucl Med Sci. 2002;15:147-151. (First author)